Abbreviations: ITP, immune thrombocytopenic purpura; TTP, thrombotic thrombocytopenic purpura; HUS, hemolytic-uremic syndrome; HELLP, hemolysis, elevated liver enzymes, low platelets syndrome; AFLP, acute fatty liver of pregnancy. 
Abstract
A mild thrombocytopenia is relatively frequent during pregnancy and has generally no consequences for either the mother or the fetus.
Although representing no threat in the majority of patients, thrombocytopenia may result from a range of pathologic conditions requiring closer monitoring and possible therapy.
Two clinical scenarios are particularly relevant for their prevalence and the issues relating to their management. The first is the presence of isolated thrombocytopenia and the differential diagnosis between primary immune thrombocytopenia and gestational thrombocytopenia. The second is thrombocytopenia associated with preeclampsia and its look-alikes and their distinction from thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.
In this review we describe a systematic approach to the diagnosis and treatment of these disease entities using a case presentation format. Our discussion will include the antenatal and perinatal management of both the mother and fetus.
Introduction
Thrombocytopenia, defined as a platelet count less than 150 x 10 9 /l, is second only to anemia as the most common hematologic abnormality encountered during pregnancy. 1 Three large series involving together more than 26,000 women suggest that its prevalence at the end of pregnancy is between 6.6% to 11.6%. [2] [3] [4] However, counts <100 x 10 9 /l, which is the definition for thrombocytopenia adopted by an
International Working Group, 5 are observed in only 1% of pregnant women. The clinician's task is to determine not only the pathophysiologic nature of the thrombocytopenia, but also the risk it poses to both mother and fetus. Treatment goals change with the dynamic state of parturition and in particular during delivery, when surgical risks and the neonate's passage through the birth canal need be considered.
We will discuss these problems using a case based approach of representative clinical scenarios and examine available evidence to help guide practice. The article will focus on the clinical characteristics and management of primary immune thrombocytopenia (ITP) and its distinction from gestational thrombocytopenia, and on the thrombotic microangiopathies of pregnancy.
The majority of available reports are based on observational studies that either examine available epidemiologic evidence or report outcomes of a single therapeutic approach. Randomized trials, however, are for the most part absent. Therefore, where opinions rely on experience we will make that distinction with the goal of outlining a rational approach to diagnosis and management of pregnancy-related thrombocytopenia.
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From thrombocytopenia to be consistent with gestational thrombocytopenia, women should have no past history of thrombocytopenia (except during a previous pregnancy), the thrombocytopenia resolved spontaneously within 1-2 months after delivery, and the fetus/newborn baby should not have suffered from thrombocytopenia (Table 3) . 9 ITP is the second most common cause of an isolated low platelet count in pregnancy, accounting for approximately 3% of women who are thrombocytopenic at delivery.
Differentiating it from gestational thrombocytopenia may be problematic if not impossible in the absence of pre-pregnancy platelet counts or a previous history of ITP, as both entities are diagnoses of exclusion. As a rule of thumb, developing a platelet count less than 100 x 10 9 /l early in pregnancy, with declining platelet counts as gestation progresses, is most consistent with ITP. As usual, situations in real life are often more complicated than in guidelines. ITP may develop even during the third trimester, and platelet counts between 50 and 80 x 10 9 /l may also be seen in gestational thrombocytopenia. Nevertheless, knowing the exact diagnosis at that stage of pregnancy changes the management very little, as will be discuss below.
In this patient a platelet count of 82 x 10 9 /l early in the second trimester requires further evaluation. 10 A mild congenital thrombocytopenia that worsens during pregnancy cannot be excluded without prior records or testing of other family members, which should be pursued, especially since some of these disorders are associated with platelet dysfunction. Our patient reported that none of the male family members had platelet disorders. Her mother had a low platelet count during pregnancy as well, whereas a sister and cousin both had normal platelet counts and history of normal deliveries.
A rare inherited cause of thrombocytopenia is type IIB von Willebrand disease (VWD). 11 Women with this condition may develop thrombocytopenia for the first The frequency of platelet counts in pregnant women with thrombocytopenia should be based on clinical reasoning, since no evidence is available. When we have a high level of confidence that a patient has gestational thrombocytopenia, we check the platelet count at the time of each routine prenatal visit. Women should also have the blood count repeated 1-3 months after delivery to assess whether spontaneous resolution of the thrombocytopenia has occurred.
If the diagnosis is ITP or uncertain, we check the platelet count every 2-4 weeks, depending on the stability of the platelet counts. If platelet counts are found to be less than 80 x 10 9 /l after week 34, we monitor them on a weekly basis.
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The presence of gestational thrombocytopenia does not generally alter the management of pregnancy. However, in a few patients the low platelet count may compromise ability to deliver epidural anesthesia and general anesthesia represents a greater risk. For women with platelet counts of 50-80 x 10 9 /l, in whom a diagnosis of ITP cannot be excluded, we give 10 mg of prednisone once daily starting ten days before the anticipated date of delivery. Others may start with a higher dose and adjust downward, but there are no published randomized trials to guide management.
Alternatively, some experts also advise a course of intravenous immunoglobulin (IVIg), 1g/kg in one or two divided doses, which may be useful both diagnostically and therapeutically. 17 We treat ITP in the first and second trimesters when the patient is symptomatic with bleeding, platelet counts are less than 30 x 10 9 /l, or a planned procedure requires a higher platelet count (see below). Despite remaining relatively stable through most of the pregnancy, platelet counts may fall during the third trimester and monitoring should be more frequent. Therapy late in gestation is generally based on the risk of maternal hemorrhage at delivery (see section below).
In the case we have described the platelet count was assessed monthly at her routine 
What can the patient expect during a subsequent pregnancy?
A review of the clinical courses of 92 women with ITP during 119 pregnancies over an 11 year period found women with previously diagnosed ITP were less likely to require therapy for ITP than those with newly diagnosed ITP, although the frequency of bleeding complications did not differ between the two groups. 18 Platelet counts at delivery were <150 x 10 9 /l in 89% of women. In most cases thrombocytopenia was mild to moderate and the pregnancies were uneventful; however, 31% required intervention to increase the platelet count at some time during their pregnancy.
Thrombocytopenia was observed in 31/109 (28.4%) of infants; 11 (10%) had platelet counts lower than 50 x 10 9 /l. Two fetal deaths were recorded, one of which was caused by hemorrhage.
What treatments are safe during pregnancy?
Women with no bleeding manifestations and platelet counts >30 x 10 9 /l do not require any treatment until delivery is imminent. Antenatal corticosteroids have not been found to affect the neonatal platelet count and
should not be administered to the near term mother with this objective. 23 Withdrawal of corticosteroids in the postpartum period must be carefully monitored and dosage tapered to avoid a rapid drop in the platelet count. If the platelet response to prednisone is suboptimal or when side effects of the drug are poorly tolerated, IVIg can be used (1g/kg in a single or 2 divided doses), either alone or in combination with small doses of prednisone, to maintain safe platelet counts. Anti-RhD immunoglobulin is not recommended as a first line agent because of concerns of acute hemolysis and anemia. Nevertheless, it has been used in refractory cases throughout pregnancy with successful outcomes. 24 If anti-RhD (50-75μg/kg) is administered to a patient while pregnant, the neonate should be monitored for a positive direct antiglobulin test (DAT), anemia and jaundice as the antibody may cross the placenta.
If the patient's response to first line agents is not adequate second line therapy may be required, although safety considerations in the pregnant patient require some change in approach. Azathioprine has been safely administered during pregnancy 25, 26 .
Although immune impairment has been reported in some exposed infants, 27 it is a reasonably safe option. High dose methylprednisolone may also be used in combination with IVIg or azathioprine for the patient who is refractory to oral corticosteroids or IVIg alone or has a less than adequate response. Cyclosporine A has not been associated with significant toxicity to mother or fetus during pregnancy when used for inflammatory bowel disease, 28 but there is no published experience on its use in ITP in pregnancy and it should be considered only when other safe second line agents have failed.
Splenectomy may induce a remission and has been reported to be associated with few complications if performed during the second trimester, 29,30 when risks of anesthesia to the fetus are minimal and uterine size will not complicate the procedure. This approach may be useful for patients who remain refractory to therapy or who experience significant toxicity with other therapies. Transplacental passage of circulating maternal antiplatelet antibodies and the risk of neonatal thrombocytopenia are not affected by splenectomy.
31-33
Many of the agents frequently used in non pregnant ITP patients may not be safe during pregnancy. Limited data are available for rituximab in pregnancy, and the use of this drug for pregnancy associated ITP cannot be recommended because of its potential for crossing the placenta. 34 Short-term therapy with danazol in combination with high dose IVIg and corticosteroids has been used for refractory thrombocytopenia in the third trimester. 35 However, danazol has been observed to cause birth defects and has been designated category X by the FDA; its use should therefore be avoided. Vinca alkaloids and cyclophosphamide, are not considered safe during pregnancy. There are no published data on the use of thrombopoietin receptor agonists in pregnancy and since their effects on the fetus are unknown they cannot be recommended.
Thrombocytopenia secondary to systemic lupus erythematosus or the antiphospholipid antibody syndrome is generally less severe than that seen with ITP.
When platelet counts are less than 30 x 10 9 /l and/or symptomatic bleeding is present, 
How should delivery be managed? What is a safe platelet count for epidural anesthesia?
ITP is not an indication for cesarean delivery. 6, 19 Mode of delivery in a pregnant patient with ITP is based on obstetric indications, with avoidance of procedures associated with increased hemorrhagic risk to the fetus (e.g., forceps, vacuum extraction and fetal scalp electrode/samples). 6 Most neonatal hemorrhages occur at 24-48 hours and are actually not related to trauma at the time of delivery.
36,37
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Determination of the fetal platelet count by fetal scalp vein blood draws or periumbilical blood sampling presents a potential hemorrhagic risk to the fetus and may inaccurately predict a low platelet count. 38 For this reason fetal platelet count measurement is not recommended.
Maternal anesthesia must be based on safety of the mother. The precise platelet count needed to safely perform neuraxial analgesia is unknown. 39, 40 American guidelines do not suggest any particular threshold but individual assessment of risks and benefits. /l, 18 and in several other cases with platelet counts between 20 and 50 x 10 9 /l. 18, 42 Nevertheless, the risk of conversion to Csection is present in every labor and we agree with current recommendations to aim for at least a level of 50 x 10 9 /l. 6 To achieve that target, various combinations of IVIG, platelet transfusions and corticosteroids can be used. The use of platelet transfusions before delivery in pregnant women with ITP has been reported in 5% to 18.9% of cases, reflecting not only different patient populations but also different practices.
18,42
For personal use only. /l occur in 5% of cases. 18 Intracranial hemorrhage has been reported in 0-1.5%. 18, 31, 32 There are no indirect ways of measuring the fetal platelet count and the correlation between maternal and fetal platelet counts is poor. 4, 31 The best predictor of severe thrombocytopenia at birth is its occurrence in an older sibling, 2, 43, 44 Maternal response to treatment does not automatically protect the newborn from the development of thrombocytopenia. On the other hand, there is no robust evidence to suggest that neonates from women with ITP poorly responsive or refractory to treatment have a higher risk of severe thrombocytopenia.
A platelet count should be obtained at delivery to determine the need for immediate therapy. The count should be performed on a cord blood sample or preferably, a peripheral blood sample. Heel-prick samples should be avoided, since clots are common and may result in artifactual thrombocytopenia. If the platelet count is normal there is no need for repeat counts, although parents should be instructed on observation for unexplained bruising or petechiae and a thorough examination performed at one week. In neonates with thrombocytopenia the platelet counts is obtained daily, since its nadir is frequently seen 2-5 days after birth. A spontaneous rise of the platelet count is usually seen by day 7; in some cases, however, thrombocytopenia may last weeks to months. 45 We request a cranial ultrasound when the platelet count at birth is less than 50 × 10 9 /l, even in the absence of symptoms. In fact, although intracranial bleeding may not have clinical manifestations, it requires immediate management and may affect the management of subsequent pregnancies.
Until it is determined that the neonate has a safe platelet count, intramuscular /l. IVIg can be repeated every few weeks if needed to maintain a safe platelet count until spontaneous recovery.
Thrombotic microangiopathies of pregnancy
Pre-eclampsia, the HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) and acute fatty liver of pregnancy (AFLP), have overlapping clinical and laboratory features with thrombotic microangiopathies that are not specific to pregnancy and may pose considerable diagnostic challenges (Table 5) . Coagulation results and creatinine were normal. The blood film confirmed true thrombocytopenia, with some giant platelets and a few red cell fragments.
For
What is the most likely etiology of her thrombocytopenia?
Preeclampsia is the second most frequent cause of thrombocytopenia developing in the late second or third trimester, accounting for 21% of cases of thrombocytopenia at the time of delivery. For It is rarely necessary to make the diagnosis.
What is the standard management of thrombotic microangiopathies of pregnancy?
The mainstay of treatment of preeclampsia/eclampsia, HELLP syndrome and AFLP is delivery of the fetus. 56 Sudden deterioration in maternal and fetal conditions is common in pregnancies complicated by these disorders. Prompt delivery is indicated for pregnancies ≥ 34 weeks of gestation, evidence of fetal distress (based on fetal heart rate monitoring and biophysical profile), or severe maternal disease (Figure 2 ). For pregnancies of less than 34 weeks' gestation and in which the maternal and fetal status is reassuring, glucocorticoids are recommended to accelerate fetal pulmonary maturity followed by delivery within 48 hours. Reversal of coagulopathy (eg, transfusion of fresh frozen plasma, cryoprecipitate, packed red blood cells and platelets) may be required prior to delivery and/or in the immediate post natal period.
The target platelet count for safe cesarean delivery is conventionally set at >50 x 
What is the most likely etiology of the thrombocytopenia?
Although pathophysiologically different, TTP and HUS share overlapping clinical features and may be difficult to discern from one another, from the pregnancy-specific disorders previously described, and from some autoimmune diseases. In many reports, the clinical difference between TTP and HUS is based on the presence of acute renal failure, which is minimal or absent in the former and dominant in the latter. The incidence of TTP/HUS among all pregnancies has been estimated to be 1 in 25,000, 63 significantly more frequent than in the general population. 64 The time of onset of TTP/HUS in pregnancy is variable, but only a minority of cases are seen during the first trimester.
TTP is associated with a deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is rarely congenital and inherited (Upshaw-Schulman syndrome) and may manifest for the first time during pregnancy. In most cases it is an acquired disorder, due to autoantibodies neutralizing ADAMTS13 activity. 65 VWF-cleaving protease deficiency can also occur in DIC, HUS, preeclampsia and HELLP. 66 However, a severe deficiency (<5% of the activity in normal plasma) appears to be specific for TTP. 
What is the management of TTP/HUS in pregnancy?
The The risk of relapse in subsequent pregnancies in case of inherited TTP is 100% in the absence of prophylactic plasma therapy, which should be instituted as early as possible in the first trimester. 73 The risk of relapse during a subsequent pregnancy in women with acquired TTP associated with severe ADAMTS13 deficiency has been reported to be about 20%. 74 Our practice is to monitor women closely throughout their pregnancy and start prophylactic plasma exchange treatment if ADAMTS13 activity falls below <10% or the blood film shows unequivocal evidence of red cell fragmentation.
Summary
Thrombocytopenia is a relatively common occurrence in pregnancy. Diagnosis is largely dependent upon timing of its onset, severity of the thrombocytopenia and the association with other abnormalities. Isolated mild thrombocytopenia may require observation alone and present no risk to the mother or fetus. More severe thrombocytopenia or that associated with hypertension, liver abnormalities, neurologic or renal abnormalities, requires consideration of the diverse pathophysiologic mechanisms. As most treatment recommendations have been based on observational reports, questions remain as to the optimal management of the mother and safe delivery of the newborn, including safety of the TPO-receptor agonists in pregnancy, and treatment of an associated prothrombotic tendency. HELLP, Hemolysis, Elevated Liver enzymes, and Low Platelets syndrome; AFLP, acute fatty liver of pregnancy; aHUS, atypical haemolytic uremic syndrome; TTP, thrombotic thrombocytopenic purpura; CAPS, catastrophic antiphospholipid syndrome; SLE, systemic lupus erythematosus. +/-rare or absent (0-20% of cases); + fairly common (20-50% of cases); ++ common (50-80% of cases); +++ very common or constant feature (80-100% of cases).
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